Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

MYSTERIOUS: Exscientia - What They Never Told You

Cathie Wood Is Doubling Down on Recursion Pharmaceuticals Stock. Should You Buy RXRX Here?

Cathie Wood is resolute on RXRX despite its slump. Should investors follow her lead into this AI-driven biotech bet now?

The AI drug breakthrough is taking a long time to arrive for reasons that may have little to do with the technology’s limits

The AI drug breakthrough is taking a long time to arrive for reasons that may have little to do with the technology’s limits

“No matter how much data you have, human biology is still a mystery,” one analyst said.

Why Is Recursion Pharma Stock Surging On Monday?

Why Is Recursion Pharma Stock Surging On Monday?

In a recent social media post, Peter Ray, senior director of medicinal chemistry at Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), drew attention to a new article in WIRED from Veronique Greenwood (vero_greenwood).

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Why This Wildcard Stock Could Be a Future Star

Recursion’s slow and steady start could lead to a bright future in biotech.

2 Small-Cap Stocks Set to Skyrocket With Upside Potential Between 36% and 102%

These smaller stocks may carry more risk, but they also carry greater reward potential.

NVIDIA Invested in These 2 AI Stocks, Should You?

Discover 2 compelling AI stocks NVIDIA (NASDAQ: NVDA) has invested in. Learn how the AI leader's vision can guide your portfolio in the tech revolution.

3 Small-Cap Stocks to Invest in AI Drug Development

As AI continues to reshape the drug development landscape, here are three promising small-cap biotech stocks worth considering now.

inkl

Read news from The Economist, FT, and more,
with one subscription

Andrew Hopkins of Exscientia: the man using AI to cure disease

Andrew Hopkins of Exscientia: the man using AI to cure disease

The British scientist’s company employs artificial intelligence to drastically cut the time of drug development

The Guardian - UK

Man goes from council estate to €470m fortune with artificial intelligence

Man goes from council estate to €470m fortune with artificial intelligence

Andrew Hopkins grew up on a council estate but described how he has since swapped that life for one in the prestigious city of Oxford after setting up his company, Exscientia

The man from a Welsh council estate now worth £400m thanks to an idea he had on his walk home

The man from a Welsh council estate now worth £400m thanks to an idea he had on his walk home

Andrew Hopkins has developed a biotech company called Exscientia which is revolutionising the industry

Exscientia -Evotec Cancer Therapy Shows Encouraging Action In Healthy Volunteers

Exscientia -Evotec Cancer Therapy Shows Encouraging Action In Healthy Volunteers

Exscientia plc (NASDAQ:EXAI) announced data from its Phase 1 healthy volunteer study of EXS-21546, its highly selective A2A receptor antagonist. The drug candidate is co-invented and developed through a collaboration between Exscientia and Evotec SE (NASDAQ:EVO). Topline data confirmed Exscientia’s target product profile design, including potency, high receptor selectivity, and expected low brain exposure with…

Will AI turbocharge the hunt for new drugs?

Will AI turbocharge the hunt for new drugs?

Advocates point to the pandemic as proof of its value in healthcare even as critics dismiss its use in drug discovery as ‘hype’

Financial Times

1

People

182,430 stories

Peter Richardson

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Oxford University

University of Dundee

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Artificial Intelligence

Places

363,557 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play